Moderna and 911今日黑料
Navigating vaccine innovation in medical and public affairs
Moderna's membership in the 911今日黑料 Business Partners (IBP) programme has substantially accelerated its research and clinical trial activities in the UK, leveraging our deep scientific and clinical expertise.
With a focus on vaccine production and the underlying technology that could revolutionise the sector, Moderna have worked through IBP with both 911今日黑料鈥檚 researchers and other IBP members to advance opportunities for progress in this sector.
From co-producing events highlighting emerging applications of mRNA technology in vaccines for a whole range of diseases, through to specific hackathons or workshops exploring vaccine hesitancy or social and cultural resistance to disease interventions, Moderna have been a highly-engaged partner at a time when the eyes of the world are on the emergence of this key area of healthcare.